FDA PMA FDA Class 3 Approved 🇺🇸 United States

Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

PMA: P910007 · Supplement: S064 · Decision Nov 8, 2023
Classifications
1
FEI Numbers
15
Registration Numbers
15

Basic Information

Device Name
Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer
Trade Name
Alinity i Total PSA Reagent Kit
PMA Number
P910007
Supplement Number
S064
Device Class
FDA Class 3
Product Code
MTF
Generic Name
Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer
Medical Specialty
Unknown
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
November 8, 2023
Date Received
August 11, 2023
Supplement Type
Real-Time Process
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

Approval for the release of Alinity i Total PSA for use with Alinity i (Alinity ci-series single and multimodule configuration) when connected to the GLP systems Track.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MTF Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer